Recent research from reputation data specialist RepTrak (Boston) indicates that the pharma industry had the largest year-over-year reputational improvement of any sector, according to its roundup of top 100 corporations. The sector saw significant gains in consumers’ perception of its citizenship and governance.  Now ranked eighth overall, the pharma industry came in just ahead of…

Sanofi announced today that it will spend €600 million ($685 million) on a new plant in Toronto to produce its differentiated influenza vaccines. The Paris-based pharma giant’s Fluzone high-dose quadrivalent influenza vaccine has four times more antigen than a standard-dose vaccine. The vaccine’s creators specifically designed it to provide superior protection against influenza for older…

President Joe Biden announced that the U.S. is set to provide $4 billion to the COVAX Facility to support access to safe and effective COVID-19 vaccines. Money appropriated by a December 2020 Congressional vote will comprise an initial $2 billion contribution to Gavi, the Vaccine Alliance for the COVAX advance market commitment (AMC) covering 92…

Since the beginning of the pandemic, much of society has pinned its hopes on the availability of a vaccine. Now that several are available across the world, there is hope, said Dr. Anthony Fauci, chief medical advisor to President Joe Biden, in a recent JAMA interview. “There’s light at the end of the tunnel.”  One thing that…

Sanofi (NYSE:SNY) shares ticked up this morning on fourth-quarter results that were mixed compared to the consensus forecast. The Paris-based company posted profits of $1.3 billion, or $1.03 per share, on sales of $11.3 billion, marking a -2.4% year-over-year revenue decline for the three months ended Dec. 31, 2020. Adjusted to exclude one-time items, earnings per…

Sanofi (NYSE:SNY) announced today that it entered into an agreement to support the manufacturing and supply of the Pfizer/BioNTech COVID-19 vaccine. Pfizer and BioNTech’s vaccine is one of two to receive FDA emergency use authorization in the U.S. and it also has clearance in Europe, having received both nods in December 2020. The deal between Sanofi…

Prominent pharmaceutical companies including Pfizer (NYSE:PFE), Sanofi (NYSE:SNY),  GlaxoSmithKline (NYSE:GSK) and Teva (NYSE: TEVA) intend to raise U.S. prices of more than 300 drugs starting Jan. 1, according to Reuters. But President-elect Joe Biden has vowed to slash drug prices. “Too many Americans cannot afford their prescription drugs, and prescription drug corporations are profiteering off of the pocketbooks of sick individuals,” he wrote in a healthcare…

Sanofi (NSDQ:SNY) and GSK (LON: GSK), which have teamed up to produce a COVID-19 vaccine candidate, have signaled their intent to work with the legal administrator of the COVAX Facility. The two companies have vowed to produce 200 million doses of a vaccine based on the protein subunit AS03 adjuvant. Governments, businesses and health organizations…

Sanofi (NYSE:SNY) and GlaxoSmithKline (NYSE:GSK) announced that they reached an agreement with the UK government to supply up to 60 million doses of a COVID-19 vaccine. Subject to a final contract, the UK government will receive the doses of a vaccine candidate developed by the two companies in partnership and based on the recombinant protein-based technology Sanofi used to…

The Trump administration has awarded Sanofi (NYSE:SNY) and GlaxoSmithKline (NYSE:GSK) a contract for up to $1.2 billion to develop, manufacture and deliver a vaccine for COVID-19, the companies announced today. The vaccine candidate is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established pandemic adjuvant (immunity-boosting) technology. Manufacturing will…